Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: A pilot study

American Journal of Gastroenterology

Volumn 94, Issue 9, 1999, Pages 2475-2481

  Funasaki, Tsutomu ^a   Tsutsumi, Mikihiro ^a   Takase, Shujiro ^a   Tsuchishima, Mutsumi ^a   Ueshima, Yasuhiro ^a   Urashima, Sachio ^a   Shimanaka, Koshi ^a   Itoh, Tohoru ^a   Kawahara, Hiromu ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCARPAMINE; PRODRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; ASCITES; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PRODRUGS;

EID: 0033198637     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01379.x     Document Type: Article

References (19)

1. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: Natural history and prognostic factors. Hepatology 1987;7: 122-8.
2. Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 1989;321: 1632-8.
3. Strauss E, De Sa MDFG, Lacet CMC, et al. Standardization of a therapeutic approach for ascites due to chronic liver disease: A prospective study of 100 cases. Gastroenterol End Dig 1985;4:79-86.
4. Gines P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N EngI J Med 1991:325:829-35.
5. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
6. Runyon B A. Acites. In: Schiff L, Schiff ER, eds. Diseases of the liver, Volume 2. 7th ed. Philadelphia: J.B. Lippincott Company, 1993:990-1015.
7. McDonald RH, Goldberg LI, McNay JL. Effects of dopamine in man. J Clin Invest 1964;43:1116-24.
8. Tally RC, Goldberg LI, Johnson C. A hemodynamic comparison of dopamine and isoproterenol in patients with patients with shock. Circulation 1969;39:361-78.
9. Goldberg LI. Cardiovascular and renal actions of dopamine. Pharmacol Rev 1972;24:l-9.
10. Merits I, Anderson DJ, Sounders RC. Species differences in the metabolism of orally administered dopamine-14C and N-alanyldopamine-14C. Drug Metab Dispos 1973;l:691-7.
11. Yamaguchi I, Nishiyama S, Akimoto Y, et al. A novel orally active dopamine prodrug TA-870.1. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. J Cardiovasc Pharmacol 1989;13:879-86.
12. Nishiyama S, Yamaguchi I, Akimoto Y, et al. A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug. J Cardiovasc Pharmacol 1989; 14:17583.
13. Nishiyama S, Yamaguchi I, Akimoto Y, et al. A novel orally active dopamine prodrug TA-870. III. Positive inotropic effect and cardiorenal selectivity in anesthetized dogs. J Cardiovasc Pharmacol 1990;15:283-90.
14. Casgrande C, Merlo L, LaRegina A. Development of dopaminergic drugs for the chronic treatment of congestive heart failure. J Auton Pharmacol 1990;10:s85-93.
15. Yoshikawa M, Endo H, Komatsu K, et al. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)O.O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. Drug Metab Dispos 1990;18:212-7.
16. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
17. Kumada T, Kawai C, Sakuma A. Evaluation of a new oral dopamine (TA-870) in patients with circulatory failure under drip infusion of dopamine: Multiclinic double-blind group comparative study versus dopamine hydrochloride injectable. J Clin Ther Med 1991;7:1521-42.
18. Ozawa N, Mori N, Nakahara K, et al. Effect of the dopamine prodrug TA-870 on renal function in patients with renal hypofunction. Jap J Pharmacol Ther 1987;15:309-17.
19. Sherlock S, Senewirantne B, Scott A, et al. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966;l:1049-53.